EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Inhibition of the GSK3β/Nav1.6 complex suppresses early‐stage Alzheimer's hyperexcitability

Timothy John Baumgartner, Manuel Silva-Pérez, Zahra Haghighijoo, Nolan Michael Dvorak, Aditya Kumar Singh, Nana Aboadwe Goode, Jully Singh, Berenice Gutierrez Grebenkova, Mate Marosi, Jessica Di Re, Leandra Koff, Wissarut Wijitrmektong und 11 weitere

Alzheimer's & Dementia · 2025-07 · 21 (7)

DOI: 10.1002/alz.70507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 28.07.2025. Verfasst von Timothy John Baumgartner und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Glycogen Synthase Kinase 3 beta, NAV1.6 Voltage-Gated Sodium Channel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIEHS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Network hyperexcitability (NH) is observed in patients with early‐stage Alzheimer's disease (AD), emerging decades before cognitive decline. A key molecular determinant of NH is voltage‐gated Na+ channel 1.6 (Nav1.6), which mediates action potential firing in CA1 hippocampal neurons. Ameliorating NH through inhibition of the glycogen‐synthase kinase 3β (GSK3β/Nav1.6 complex may provide immediate benefits to cognition and memory and slow AD progression. METHODS Hight‐throughput virtual screening and multiple in vitro biological assays were utilized to identify compound 1063. Patch‐clamp electrophysiology and electroencephalogram recordings were utilized to functionally assess 1063 in models of AD neuropathology. RESULTS Building on previous studies identifying GSK3β as a modulatory protein binding to the Nav1.6 C‐terminal domain (CTD), we identified 1063, a brain‐penetrant small molecule that inhibits GSK3β/Nav1.6 complex assembly and reduces NH in AD rodent models. DISCUSSION These results demonstrate the potential of the GSK3β/Nav1.6 complex as a therapeutic target for NH in early‐stage AD. Highlights The glycogen synthase kinase 3‐β (GSK3β)/Nav1.6 complex is a potential target for hyperexcitability in early Alzheimer's disease (AD). Compound 1063 dose‐dependently decreases GSK3β/Nav1.6 complex assembly. Compound 1063 is functionally specific for Nav1.6 over other central nervous system (CNS) Nav isoforms. Ex vivo functional studies provide evidence for target engagement. 1063 dose‐dependently reduces epileptiform activity in AD rodent model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseGlycogen Synthase Kinase 3 betaNAV1.6 Voltage-Gated Sodium ChannelAnimalsHumansDisease Models, AnimalNeuronsPatch-Clamp TechniquesMice, TransgenicElectroencephalographyMiceAction PotentialsAmyloid beta-PeptidesMale

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid beta‐induced hyperexcitabilityglycogen synthase kinase 3βnav1.6network hyperactivityneuronal hyperexcitabilitysmall molecule drug discoveryvoltage‐gated sodium channel

Substanzen

Glycogen Synthase Kinase 3 betaNAV1.6 Voltage-Gated Sodium ChannelAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Department of Neuroscience, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Neurology, University of Texas Medical, Branch, Galveston, Texas, USA.
  • Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, Texas, USA.
  • IonTX Inc., Friendswood, Texas, USA.
  • Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, Texas, USA.

Förderung

  • NIGMS NIH HHS
  • NIEHS NIH HHS
  • NIDDK NIH HHS
  • Moody Brain Health Institute Pilot Project
  • NIMH NIH HHS
  • NIA NIH HHS
  • NIH HHS
  • Houston Area Molecular Biophysics Program

Zitieren

APA

Baumgartner, T. J., Silva-Pérez, M., Haghighijoo, Z., Dvorak, N. M., Singh, A. K., Goode, N. A., Singh, J., Grebenkova, B. G., Marosi, M., Di Re, J., Koff, L., Wijitrmektong, W., Bala, M., Liao, H., Lijffijt, M., Szafran, A. T., Bolt, M. J., Mancini, M. A., Cuny, G. D., …, & Laezza, F. (2025). Inhibition of the GSK3β/Nav1.6 complex suppresses early‐stage Alzheimer's hyperexcitability. Alzheimer's & Dementia, 21(7). https://doi.org/10.1002/alz.70507

Vancouver

Baumgartner TJ, Silva-Pérez M, Haghighijoo Z, Dvorak NM, Singh AK, Goode NA, et al. Inhibition of the GSK3β/Nav1.6 complex suppresses early‐stage Alzheimer's hyperexcitability. Alzheimer's & Dementia. 2025;21(7). doi:10.1002/alz.70507

BibTeX
@article{Baumgartner2025,
  author = {Baumgartner, Timothy John and Silva-Pérez, Manuel and Haghighijoo, Zahra and Dvorak, Nolan Michael and Singh, Aditya Kumar and Goode, Nana Aboadwe and Singh, Jully and Grebenkova, Berenice Gutierrez and Marosi, Mate and Di Re, Jessica and Koff, Leandra and Wijitrmektong, Wissarut and Bala, Manu and Liao, Hanyue and Lijffijt, Marijn and Szafran, Adam Thomas and Bolt, Michael James and Mancini, Michael A and Cuny, Gregory D and Chow, Diana Shu-Lian and Limon, Agenor and Chin, Jeannie and Laezza, Fernanda},
  title = {Inhibition of the GSK3β/Nav1.6 complex suppresses early‐stage Alzheimer's hyperexcitability},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {7},
  doi = {10.1002/alz.70507}
}
Kostenlos starten →